News

GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies on a ‘rep... GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies on a ‘repurposed’ drug candidate Drug candidate SNR 1611, discovered through screening platform “ATRIVIEW”, set to prov... BioSpectator 2019.09.19
GENUV, focusing on the development of new drugs for neurodegenerative ... [Hidden Champions on the Move] GENUV, focusing on the development of new drugs for neurodegenerative diseases including Alzheimer’s … develops ‘Drug Screening’ technology CEO Sung-Ho Han... Korea SportsBiz 2019.07.25
Targeting ‘Neurodegenerative Disease’, GENUV’s New Drug Development St... Targeting ‘Neurodegenerative Disease’, GENUV’s New Drug Development Strategy Building a Neural Stem Cell-Based Neuro-regenerative New Drug Screening Platform and Next Generation Transgenic Mous... BioSpectator 2019.07.09
Genuv Unveils GNUV205, a Bifunctional Fusion Protein That Potently Reg... SEOUL, Republic of Korea & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immu... BusinessWire 2022.10.13
GENUV CEO Sung-Ho Han, "To make real progress in the treatment of ALS ... Maeil Economics 2020.03.04
GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies on New Dr... MoneyToday 2019.09.19
GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies on New Dr... YoungDoctors 2019.09.19
GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies Maeil Economics 2019.09.19